COST-EFFICACY ANALYSIS OF GEFITINIB EFFICACY IN PATIENTS WITH NON OPERABLE NON SMALL CELL LUNG CANCER
Drug treatment of disseminated non small cell lung cancer (NSCLC) is an actual issue today. Both clinical and economic efficacy analysis is needed for optimal therapy selection. We performed economic efficacy assessment of gefitinib (G.) therapy in patients with non operable NSCLC who hase no E...
Saved in:
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Bashkir State Medical University
2017-01-01
|
| Series: | Креативная хирургия и онкология |
| Subjects: | |
| Online Access: | https://www.surgonco.ru/jour/article/view/111 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849696759534583808 |
|---|---|
| author | S. A. Protsenko A. V. Rudakova F. V. Moiseyenko E. V. Levchenko D. E. Matsko A. О. Ivantsov I. I. Semenov A. G. Ievleva N. V. Mitushkina A. V. Togo A. V. Novik E. N. Imyanitov V. M. Moiseyenko |
| author_facet | S. A. Protsenko A. V. Rudakova F. V. Moiseyenko E. V. Levchenko D. E. Matsko A. О. Ivantsov I. I. Semenov A. G. Ievleva N. V. Mitushkina A. V. Togo A. V. Novik E. N. Imyanitov V. M. Moiseyenko |
| author_sort | S. A. Protsenko |
| collection | DOAJ |
| description | Drug treatment of disseminated non small cell lung cancer (NSCLC) is an actual issue today. Both clinical and economic efficacy analysis is needed for optimal therapy selection. We performed economic efficacy assessment of gefitinib (G.) therapy in patients with non operable NSCLC who hase no EGFR mutation using Markov model based on results of clinical studies conducted in N.N. Petrov Research Institute of Oncology.G. increases overall survival of patients with NSCLC with EGFR mutation by 1,05 year. Cost/efficacy coefficient for G. in patients with EGFR mutation is 934 800 rub per 1 acquired year of life. Therapy with G just for patients with genetically proven mutation is dominating strategy when compared to therapy for all NSCLC patients irrespectively to mutation status (saving 211600 – 251800 rub per 1 patient taking into account equal clinical efficacy). Therapy with G. is economically justifying strategy when compared to chemotherapy (additional costs coefficient 960700 – 1010000 rub per 1 gained year of life). Thus, EGFR mutation testing with subsequent G. therapy in non operable NSCLC patients not only prolongs patient’s life but also has acceptable level of medical expenses. |
| format | Article |
| id | doaj-art-e5b353add05b45ec86743eaa42e6c519 |
| institution | DOAJ |
| issn | 2076-3093 2307-0501 |
| language | English |
| publishDate | 2017-01-01 |
| publisher | Bashkir State Medical University |
| record_format | Article |
| series | Креативная хирургия и онкология |
| spelling | doaj-art-e5b353add05b45ec86743eaa42e6c5192025-08-20T03:19:21ZengBashkir State Medical UniversityКреативная хирургия и онкология2076-30932307-05012017-01-0102465210.24060/2076-3093-2012-0-2-46-52111COST-EFFICACY ANALYSIS OF GEFITINIB EFFICACY IN PATIENTS WITH NON OPERABLE NON SMALL CELL LUNG CANCERS. A. Protsenko0A. V. Rudakova1F. V. Moiseyenko2E. V. Levchenko3D. E. Matsko4A. О. Ivantsov5I. I. Semenov6A. G. Ievleva7N. V. Mitushkina8A. V. Togo9A. V. Novik10E. N. Imyanitov11V. M. Moiseyenko12N.N. Petrov Research Institute of OncologySt. Petersburg State Chemistry-Pharmaceutical AcademyDiagnostic and Therapeutic Center of the International Institute of Biologic SystemsN.N. Petrov Research Institute of OncologyN.N. Petrov Research Institute of OncologyN.N. Petrov Research Institute of OncologyN.N. Petrov Research Institute of OncologyN.N. Petrov Research Institute of OncologyN.N. Petrov Research Institute of OncologyN.N. Petrov Research Institute of OncologyN.N. Petrov Research Institute of OncologyN.N. Petrov Research Institute of OncologyDiagnostic and Therapeutic Center of the International Institute of Biologic SystemsDrug treatment of disseminated non small cell lung cancer (NSCLC) is an actual issue today. Both clinical and economic efficacy analysis is needed for optimal therapy selection. We performed economic efficacy assessment of gefitinib (G.) therapy in patients with non operable NSCLC who hase no EGFR mutation using Markov model based on results of clinical studies conducted in N.N. Petrov Research Institute of Oncology.G. increases overall survival of patients with NSCLC with EGFR mutation by 1,05 year. Cost/efficacy coefficient for G. in patients with EGFR mutation is 934 800 rub per 1 acquired year of life. Therapy with G just for patients with genetically proven mutation is dominating strategy when compared to therapy for all NSCLC patients irrespectively to mutation status (saving 211600 – 251800 rub per 1 patient taking into account equal clinical efficacy). Therapy with G. is economically justifying strategy when compared to chemotherapy (additional costs coefficient 960700 – 1010000 rub per 1 gained year of life). Thus, EGFR mutation testing with subsequent G. therapy in non operable NSCLC patients not only prolongs patient’s life but also has acceptable level of medical expenses.https://www.surgonco.ru/jour/article/view/111non-small-cell lung cancergefitinibcost-efficacy analysis |
| spellingShingle | S. A. Protsenko A. V. Rudakova F. V. Moiseyenko E. V. Levchenko D. E. Matsko A. О. Ivantsov I. I. Semenov A. G. Ievleva N. V. Mitushkina A. V. Togo A. V. Novik E. N. Imyanitov V. M. Moiseyenko COST-EFFICACY ANALYSIS OF GEFITINIB EFFICACY IN PATIENTS WITH NON OPERABLE NON SMALL CELL LUNG CANCER Креативная хирургия и онкология non-small-cell lung cancer gefitinib cost-efficacy analysis |
| title | COST-EFFICACY ANALYSIS OF GEFITINIB EFFICACY IN PATIENTS WITH NON OPERABLE NON SMALL CELL LUNG CANCER |
| title_full | COST-EFFICACY ANALYSIS OF GEFITINIB EFFICACY IN PATIENTS WITH NON OPERABLE NON SMALL CELL LUNG CANCER |
| title_fullStr | COST-EFFICACY ANALYSIS OF GEFITINIB EFFICACY IN PATIENTS WITH NON OPERABLE NON SMALL CELL LUNG CANCER |
| title_full_unstemmed | COST-EFFICACY ANALYSIS OF GEFITINIB EFFICACY IN PATIENTS WITH NON OPERABLE NON SMALL CELL LUNG CANCER |
| title_short | COST-EFFICACY ANALYSIS OF GEFITINIB EFFICACY IN PATIENTS WITH NON OPERABLE NON SMALL CELL LUNG CANCER |
| title_sort | cost efficacy analysis of gefitinib efficacy in patients with non operable non small cell lung cancer |
| topic | non-small-cell lung cancer gefitinib cost-efficacy analysis |
| url | https://www.surgonco.ru/jour/article/view/111 |
| work_keys_str_mv | AT saprotsenko costefficacyanalysisofgefitinibefficacyinpatientswithnonoperablenonsmallcelllungcancer AT avrudakova costefficacyanalysisofgefitinibefficacyinpatientswithnonoperablenonsmallcelllungcancer AT fvmoiseyenko costefficacyanalysisofgefitinibefficacyinpatientswithnonoperablenonsmallcelllungcancer AT evlevchenko costefficacyanalysisofgefitinibefficacyinpatientswithnonoperablenonsmallcelllungcancer AT dematsko costefficacyanalysisofgefitinibefficacyinpatientswithnonoperablenonsmallcelllungcancer AT aoivantsov costefficacyanalysisofgefitinibefficacyinpatientswithnonoperablenonsmallcelllungcancer AT iisemenov costefficacyanalysisofgefitinibefficacyinpatientswithnonoperablenonsmallcelllungcancer AT agievleva costefficacyanalysisofgefitinibefficacyinpatientswithnonoperablenonsmallcelllungcancer AT nvmitushkina costefficacyanalysisofgefitinibefficacyinpatientswithnonoperablenonsmallcelllungcancer AT avtogo costefficacyanalysisofgefitinibefficacyinpatientswithnonoperablenonsmallcelllungcancer AT avnovik costefficacyanalysisofgefitinibefficacyinpatientswithnonoperablenonsmallcelllungcancer AT enimyanitov costefficacyanalysisofgefitinibefficacyinpatientswithnonoperablenonsmallcelllungcancer AT vmmoiseyenko costefficacyanalysisofgefitinibefficacyinpatientswithnonoperablenonsmallcelllungcancer |